<DOC>
	<DOCNO>NCT00742690</DOCNO>
	<brief_summary>It well know terlipressin albumin improve renal function patient cirrhosis type 1 HRS . In previous study terlipressin use either intravenous bolus move initial dose 0.5-1 mg/4 hr continuous intravenous infusion initial dose 2 mg/24 h. Up two schedule i.v . administration terlipressin never compare . Nevertheless , hypothesize continuous intravenous infusion assures steady profile effect portal pressure patient cirrhosis . Thus , aim study compare terlipressin give i.v . bolus vs terlipressin give continuous intravenous infusion treatment type 1 HRS patient cirrhosis .</brief_summary>
	<brief_title>Terlipressin Given As I.V . Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Patients cirrhosis type 1 HRS HCC beyond Milan Criteria , septic shock ( systolic arterial pressure &lt; 90 mmHg , Significant heart respiratory failure , Peripheral arteriophaty clinically significant , Previous heart stroke significant alteration ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>type 1 hepatorenal syndrome</keyword>
	<keyword>terlipressin</keyword>
	<keyword>albumin</keyword>
	<keyword>effective circulating volume</keyword>
	<keyword>Patients</keyword>
	<keyword />
</DOC>